Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (211-220 of 436) with videos related to

Pageof 44
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2005
The hepatotoxicity of antifungal medications in bone marrow transplant recipientsMichael A Fischer, Wolfgang C Winkelmayer, Robert H Rubin, et al.
Journal of General Internal Medicine|June 26, 2013
Physician trainees' interactions with the pharmaceutical industryKirsten E Austad, Jerry Avorn, Jessica M Franklin, et al.
Health Affairs (Project Hope)|October 8, 2014
Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugsAaron S Kesselheim, Yongtian Tina Tan, Jonathan J Darrow, et al.
Health Affairs (Project Hope)|May 1, 2023
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously EstimatedFrazer A Tessema, Rachel E Barenie, Jerry Avorn, et al.
Journal of Clinical Epidemiology|July 11, 2006
Selective prescribing led to overestimation of the benefits of lipid-lowering drugsRobert J Glynn, Sebastian Schneeweiss, Philip S Wang, et al.
The Patient|September 23, 2018
General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice ExperimentMehdi Najafzadeh, Sebastian Schneeweiss, Niteesh K Choudhry, et al.
Annals of Internal Medicine|August 21, 2023
The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited EvidenceLiam Bendicksen, Diana M Zuckerman, Jerry Avorn, et al.
The American Journal of Managed Care|December 4, 2015
Medication adherence and healthcare disparities: impact of statin co-payment reductionJennifer Lewey, William H Shrank, Jerry Avorn, et al.
Journal of General Internal Medicine|February 17, 2018
Application and impact of run-in studiesMichael Fralick, Jerry Avorn, Jessica M Franklin, et al.
JAMA Oncology|April 4, 2024
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer TherapiesAriadna Tibau, Thomas J Hwang, Consolacion Molto, et al.
Pageof 44

Showing results (211-220 of 436) with videos related to

Sort By:
Pageof 44
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 12, 2005
The hepatotoxicity of antifungal medications in bone marrow transplant recipientsMichael A Fischer, Wolfgang C Winkelmayer, Robert H Rubin, et al.
Journal of General Internal Medicine|June 26, 2013
Physician trainees' interactions with the pharmaceutical industryKirsten E Austad, Jerry Avorn, Jessica M Franklin, et al.
Health Affairs (Project Hope)|October 8, 2014
Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugsAaron S Kesselheim, Yongtian Tina Tan, Jonathan J Darrow, et al.
Health Affairs (Project Hope)|May 1, 2023
Federal Funding For Discovery And Development Of Costly HIV Drugs Was Far More Than Previously EstimatedFrazer A Tessema, Rachel E Barenie, Jerry Avorn, et al.
Journal of Clinical Epidemiology|July 11, 2006
Selective prescribing led to overestimation of the benefits of lipid-lowering drugsRobert J Glynn, Sebastian Schneeweiss, Philip S Wang, et al.
The Patient|September 23, 2018
General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice ExperimentMehdi Najafzadeh, Sebastian Schneeweiss, Niteesh K Choudhry, et al.
Annals of Internal Medicine|August 21, 2023
The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited EvidenceLiam Bendicksen, Diana M Zuckerman, Jerry Avorn, et al.
The American Journal of Managed Care|December 4, 2015
Medication adherence and healthcare disparities: impact of statin co-payment reductionJennifer Lewey, William H Shrank, Jerry Avorn, et al.
Journal of General Internal Medicine|February 17, 2018
Application and impact of run-in studiesMichael Fralick, Jerry Avorn, Jessica M Franklin, et al.
JAMA Oncology|April 4, 2024
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer TherapiesAriadna Tibau, Thomas J Hwang, Consolacion Molto, et al.
Pageof 44